Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY – Research Report), Edesa Biotech (EDSA – Research Report) and Ocular Therapeutix (OCUL – Research Report).
Incyte (INCY)
In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Incyte, with a price target of $64.00. The company’s shares closed last Tuesday at $59.34.
According to TipRanks.com, Purohit has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte with a $73.31 average price target, which is a 22.1% upside from current levels. In a report issued on February 9, Mizuho Securities also initiated coverage with a Hold rating on the stock with a $77.00 price target.
See today’s best-performing stocks on TipRanks >>
Edesa Biotech (EDSA)
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Edesa Biotech today and set a price target of $21.00. The company’s shares closed last Tuesday at $5.00.
According to TipRanks.com, Bernardino is a 4-star analyst with an average return of
Edesa Biotech has an analyst consensus of Moderate Buy, with a price target consensus of $21.00.
Ocular Therapeutix (OCUL)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Ocular Therapeutix today and set a price target of $12.00. The company’s shares closed last Tuesday at $5.62.
According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocular Therapeutix with a $13.40 average price target, implying a 132.2% upside from current levels. In a report issued on February 9, Bank of America Securities also initiated coverage with a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on INCY:
